×
About 5,552 results

ALLMedicine™ Chronic Myelogenous Leukemia Center

Research & Reviews  2,579 results

Donor-Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation.
https://doi.org/10.3390/curroncol28010067
Current Oncology (Toronto, Ont.); Kum E, Jagelaviciute G et. al.

Jan 27th, 2021 - Patients with a variety of blood, immune, and metabolic disorders may require an allogeneic hematopoietic stem cell transplant as part of their treatment. However, over 70% of these patients do not have a matched sibling donor and require an alter...

Extramedullary Blast Crisis of Chronic Myelogenous Leukemia With a Skin Lesion: A Case ...
https://doi.org/10.1097/DAD.0000000000001897
The American Journal of Dermatopathology; Qi J, Zhang F et. al.

Jan 22nd, 2021 - Extramedullary blast crisis of chronic myeloid leukemia (CML) is defined as extramedullary disease composed of blasts regardless of the proliferation of blasts in the bone marrow. The commonly affected sites are the lymph node, central nervous sys...

KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806474
Theranostics Zhang C, Shen L et. al.

Jan 18th, 2021 - Rationale: Despite landmark therapy of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKIs), drug resistance remains problematic. Cancer pathogenesis involves epigenetic dysregulation and in particular, histone lysine demethyl...

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782553
Nature Communications; Lei H, Xu HZ et. al.

Jan 5th, 2021 - Identifying novel drug targets to overcome resistance to tyrosine kinase inhibitors (TKIs) and eradicating leukemia stem/progenitor cells are required for the treatment of chronic myelogenous leukemia (CML). Here, we show that ubiquitin-specific p...

Systematic analysis reveals a lncRNA-miRNA-mRNA network associated with dasatinib resis...
https://doi.org/10.21037/apm-20-343
Annals of Palliative Medicine; Luo J, Gao Y et. al.

Dec 11th, 2020 - Chronic myelogenous leukemia (CML) is a malignant tumor formed by the clonal proliferation of bone marrow hematopoietic stem cells. CML is a relatively rare disease, mainly affecting elderly patients, but the prevalence of CML is expected to incre...

see more →

Guidelines  9 results

JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myel...
https://doi.org/10.1007/s12185-017-2330-1
International Journal of Hematology; Usui N

Sep 24th, 2017 - JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).|2017|Usui N,|administration & dosage,administration & dosage,administration & dosage,administration &...

Chronic Myelogenous Leukemia, Version 1.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234105
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Radich JP et. al.

Nov 14th, 2013 - The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring m...

Chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2012.0009
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Abboud CN et. al.

Jan 9th, 2012 - Chronic myelogenous leukemia.|2012|O'Brien S,Abboud CN,Akhtari M,Altman J,Berman E,|therapeutic use,diagnosis,drug therapy,therapy,therapeutic use,

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
https://doi.org/10.6004/jnccn.2009.0065
Journal of the National Comprehensive Cancer Network : JN... O'Brien S, Berman E et. al.

Nov 2nd, 2009 - NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.|2009|O'Brien S,Berman E,Borghaei H,Deangelo DJ,Devetten MP,|therapeutic use,diagnosis,drug therapy,surgery,

Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance muta...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607559
The Journal of Molecular Diagnostics : JMD; Jones D, Kamel-Reid S et. al.

Dec 19th, 2008 - The BCR-ABL tyrosine kinase produced by the t(9;22)(q34;q11) translocation, also known as the Philadelphia chromosome, is the initiating event in chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). Targeting of BCR-ABL with ...

see more →

Drugs  35 results see all →

Clinicaltrials.gov  2,775 results

Busulfan - busulfan injection-Pharmascience Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fe44f9-7747-4909-b927-3b24aa6e7e09

Jan 31st, 2021 - Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is an alkylating drug ind...

Donor-Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation.
https://doi.org/10.3390/curroncol28010067
Current Oncology (Toronto, Ont.); Kum E, Jagelaviciute G et. al.

Jan 27th, 2021 - Patients with a variety of blood, immune, and metabolic disorders may require an allogeneic hematopoietic stem cell transplant as part of their treatment. However, over 70% of these patients do not have a matched sibling donor and require an alter...

Extramedullary Blast Crisis of Chronic Myelogenous Leukemia With a Skin Lesion: A Case ...
https://doi.org/10.1097/DAD.0000000000001897
The American Journal of Dermatopathology; Qi J, Zhang F et. al.

Jan 22nd, 2021 - Extramedullary blast crisis of chronic myeloid leukemia (CML) is defined as extramedullary disease composed of blasts regardless of the proliferation of blasts in the bone marrow. The commonly affected sites are the lymph node, central nervous sys...

KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806474
Theranostics Zhang C, Shen L et. al.

Jan 18th, 2021 - Rationale: Despite landmark therapy of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKIs), drug resistance remains problematic. Cancer pathogenesis involves epigenetic dysregulation and in particular, histone lysine demethyl...

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782553
Nature Communications; Lei H, Xu HZ et. al.

Jan 5th, 2021 - Identifying novel drug targets to overcome resistance to tyrosine kinase inhibitors (TKIs) and eradicating leukemia stem/progenitor cells are required for the treatment of chronic myelogenous leukemia (CML). Here, we show that ubiquitin-specific p...

see more →

News  145 results

A 70-Year-Old Man With Splenomegaly: Osmosis USMLE Study Question
https://www.medscape.com/viewarticle/893938_2

Aug 6th, 2020 - Massive splenomegaly is most characteristic of chronic myelogenous leukemia (CML) and hairy cell leukemia (HCL). CML is a neoplastic proliferation of mature myeloid cells, whereas HCL is a neoplastic proliferation of mature B cells. TRAP staining ...

Pyoderma Gangrenosum Developing After Chest Tube Placement in a Patient With Chronic Lymphocytic Leukemia
https://www.mdedge.com/dermatology/article/213731/wounds/pyoderma-gangrenosum-developing-after-chest-tube-placement-patient/page/0/1?channel=45

Dec 6th, 2019 - Comment Pathogenesis of PG Pyoderma gangrenosum lies in the spectrum of neutrophilic dermatoses, which are characterized histologically by a pandermal neutrophilic infiltrate without evidence of an infectious cause or true vasculitis. Clinically,.

Atraumatic splenic rupture as an initial presentation of chronic myelogenous leukemia
https://www.mdedge.com/hematology-oncology/article/137089/leukemia-myelodysplasia-transplantation/atraumatic-splenic
Eric Frost et al

Mar 17th, 2018 - Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm associated with the fusion of the BCR gene located on chromosome 22 and the ABL1 gene on chromosome 9. The fusion results in a reciprocal translocation between chromosomes 9 and 2.

Drug could improve treatment of CML, team says
https://www.mdedge.com/hematology-oncology/article/185091/leukemia-myelodysplasia-transplantation/drug-could-improve-treatment-cml
HT Staff

Mar 7th, 2018 - Lab mouse A microRNA-targeting drug could improve the effectiveness of tyrosine kinase inhibitors (TKIs) against chronic myelogenous leukemia (CML), according to preclinical research published in Nature Medicine. The drug, miristen, targets miR-12.

CHMP backs bosutinib for newly diagnosed CML
https://www.mdedge.com/hematology-oncology/article/185107/leukemia-myelodysplasia-transplantation/chmp-backs-bosutinib-newly-diagnosed
HT Staff

Feb 28th, 2018 - Image by Difu Wu CML cells The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approved use of bosutinib (BOSULIF) to include treatment of patients with newly diagnosed, chronic phase.

see more →

Patient Education  9 results see all →